Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Alan P Skarbnik, MD, Michele L. Donato, MD, Robert Korngold, PhD, Rena Feinman, PhD, Scott D. Rowley, MD, Andre Goy, MD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, David S Siegel, MD PhD, Tatyana A. Feldman, MD, Noa Biran, MD, Lori A. Leslie, MD, Michael B Atkins, MD, Andrew L. Pecora, MD

Blood (2018) 132 (Supplement 1): 256.

https://doi.org/10.1182/blood-2018-99-113586

Published: 2018

Journal Articles

Predicting Treatment Response and Survival of Multiple Myeloma with the Xbp-1 Co-Expression Gene Module

Xuzhang Lu, PhD, Fan Xiaolong, Jia Zhuxia, PhD, He Jinyuan, PhD, Cai Xiaohui, MD

Blood (2018) 132 (Supplement 1): 5590.

https://doi.org/10.1182/blood-2018-99-111695

Published: 2018

Journal Articles

Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins

Zemin Ren, Harmen van Andel, Wim de Lau, Robin B. Hartholt, Madelon M. Maurice, Hans Clevers, Marie José Kersten, Marcel Spaargaren, Steven T. Pals

Blood (2018) 131 (9): 982–994.

https://doi.org/10.1182/blood-2017-07-797050

Published: 2018

Includes: Supplemental data

Journal Articles

MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia

Lauren Shelby Page, BS, Xiaodong Wang, PhD, H. Shelton Earp, III, MD, Stephen Frye, PhD, Craig T Jordan, PhD, Alisa B. Lee-Sherick, MD

Blood (2016) 128 (22): 4044.

https://doi.org/10.1182/blood.V128.22.4044.4044

Published: 2016

Journal Articles

Adaptation of Marrow Osteoblast Morphology Mediated By a Hematopoietic-Derived Endosteal Cell Is Critical for Donor HSC Engraftment after BMT

Kathleen Overholt, MD, Satoru Otsuru, Victoria Best, Adam Guess, Timothy S. Olson, MD PhD, Massimo Dominici, MD, Edwin M. Horwitz, MD PhD

Blood (2015) 126 (23): 3603.

https://doi.org/10.1182/blood.V126.23.3603.3603

Published: 2015

Journal Articles

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Mu Hao, MD PhD, Meirong Zang, PhD, Yan Xu, MDPhD, Yu Qin, MD PhD, Lei Zhao, MD PhD, Shuhui Deng, MD PhD, Weiwei Sui, MD, Gang An, MDPhD, Zengjun Li, MD PhD, Yi Shuhua, MD PhD, Fenghuang Zhan, MD PhD, Lugui Qiu, MD PhD

Blood (2015) 126 (23): 4186.

https://doi.org/10.1182/blood.V126.23.4186.4186

Published: 2015

Journal Articles

Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma

Mu Hao, MD PhD, Zhimin Gu, PhD, Reinaldo Franqui Machin, Hongwei Xu, Gregory S. Thomas, PhD, Lugui Qiu, MD PhD, Guido J Tricot, MD PhD, Fenghuang Zhan, MD PhD

Blood (2015) 126 (23): 839.

https://doi.org/10.1182/blood.V126.23.839.839

Published: 2015

Journal Articles

Impact of HLA of Winning Cord Blood Unit on Outcomes after Double Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee Cellular Therapy and Immunobiology Working Party and the Acute Leukemia Working Party of the EBMT

Blood (2015) 126 (23): 3111.

https://doi.org/10.1182/blood.V126.23.3111.3111

Published: 2015

Journal Articles

Deletion of Sbds from Hematopoietic Progenitors Causes Neutropenia in a Mouse Model of Shwachman-Diamond Syndrome By Specifically Blocking Myeloid Lineage Progression at Late Differentiation Stages

Noemi A. Zambetti, Paulina M.H. Van Strien, Marijke G. Valkhof, Maria N. Adisty, Eric M. J. Bindels, PhD, Remco M. Hoogenboezem, Mathijs A. Sanders, MSc, Johanna M. Rommens, PhD, Ivo P. Touw, PhD, Marc H.G.P. Raaijmakers, MD PhD

Blood (2014) 124 (21): 355.

https://doi.org/10.1182/blood.V124.21.355.355

Published: 2014

Journal Articles

Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma

Irena Misiewicz-Krzeminska, PhD, Maria Eugenia Sarasquete, PhD, Carolina Vicente-Dueñas, PhD, Patryk Krzeminski, PhD, Katarzyna Wiktorska, PhD, Dalia Quwaider, Elizabeta A. Rojas, Rocío Corral, Luis Antonio Corchete, Ana A. Martin, MD, Fernando Escalante, Abelardo Bárez, Juan Luis Garcia, PhD, Isidro Sanchez-Garcia, MD PhD, Ramón García-Sanz, MD PhD, Jesus F. San Miguel, Norma Carmen Gutierrez, PhD MD

Blood (2014) 124 (21): 2001.

https://doi.org/10.1182/blood.V124.21.2001.2001

Published: 2014

Journal Articles

Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma

Jagadish Kummetha Venkata, PhD, Robert K Stuart, Luciano J Costa, MD, PhD, Ningfei An, PhD, Houjian Cai, PhD, Woodrow J. Coker, MD, Jin Song, PhD, Kiwana Gibbs, Terri Matson, Charles D Smith, Yubin Kang, MD.

Blood (2013) 122 (21): 3163.

https://doi.org/10.1182/blood.V122.21.3163.3163

Published: 2013

Journal Articles

High Trip13 and Low P31 Comet Cause Drug Resistance and Poor Prognosis In Multiple Myeloma

Yi Tao, MD&PhD, Zhimin Gu, PhD, Ye Yang, PhD, Hongwei Xu, DDS, Xiaojing Hu, Guido J. Tricot, M.D., Ph.D., Fenghuang Zhan, MD&PhD, Jumei Shi, MD, PhD

Blood (2013) 122 (21): 3820.

https://doi.org/10.1182/blood.V122.21.3820.3820

Published: 2013

Journal Articles

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Yuji Shimura, MD, Junya Kuroda, MD, PhD, Hisao Nagoshi, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Miki Kiyota, MD, Ryuko Nakayama, MD, Shinsuke Mizutani, MD, Yoshiaki Chinen, MD, Natsumi Sakamoto, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masaki Ri, MD, PhD, Yukimasa Shiotsu, PhD, Shinsuke Iida, MD, PhD, Tomohiko Taki, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 2945.

https://doi.org/10.1182/blood.V120.21.2945.2945

Published: 2012

Journal Articles

Identification of the Novel Chimeric Gene, PVT1-WWOX , in Multiple Myeloma with 8q24 Abnormality

Hisao Nagoshi, MD, Tomohiko Taki, MD, PhD, Kazuhiro Nishida, MD, PhD, Junya Kuroda, MD, PhD, Yoshiaki Chinen, MD, Satoru Kobayashi, Yuichi Yokokawa, MD, Mio Yamamoto-Sugitani, MD, PhD, Tsutomu Kobayashi, MD, PhD, Yosuke Matsumoto, MD, PhD, Shigeo Horiike, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2012) 120 (21): 1823.

https://doi.org/10.1182/blood.V120.21.1823.1823

Published: 2012

Journal Articles

T-Cell Profiling Shows Marked Differences in Gene Expression Between Tumour Infiltrating (TIL) and Peripheral Blood (PB) Antibody-Bead Selected T-Cells From Fresh Lymph Node and PB Samples in Follicular Non-Hodgkin's Lymphoma (FL): Possible implications for Immunomodulatory Therapy

Saad M B Rassam, MD, FRCP, FRCPath, Farooq Malik, BSc, PhD, John Schofield, MD, FRCPath, Haytham Ali, MD, FRCS, Ghulam J. Mufti, MD

Blood (2012) 120 (21): 683.

https://doi.org/10.1182/blood.V120.21.683.683

Published: 2012

Journal Articles

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

Albrecht Reichle, Christina Hart, Matthias Grube, Reinhard Andreesen

Blood (2012) 120 (21): 5029.

https://doi.org/10.1182/blood.V120.21.5029.5029

Published: 2012

Journal Articles

The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma

Domenica Ronchetti, Katia Todoerti, Giacomo Tuana, PhD, Luca Agnelli, PhD, Laura Mosca, PhD, Marta Lionetti, PhD, Sonia Fabris, PhD, Patrizia Colapietro, Monica Miozzo, Manlio Ferrarini, MD, Pierfrancesco Tassone, MD, Antonino Neri

Blood (2012) 120 (21): 3955.

https://doi.org/10.1182/blood.V120.21.3955.3955

Published: 2012

Journal Articles

Alterations in the Circulating Nitrite Levels and Expression of NOS Isoforms in the Neutrophils of AML Patients

Anil K Tripathi, MD, M Jain, A K Singh, M K Barthwal, Ashutosh Kumar, M Dikshit

Blood (2012) 120 (21): 4325.

https://doi.org/10.1182/blood.V120.21.4325.4325

Published: 2012

Journal Articles

The Effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells

Guido J. Tricot, MD, PhD, Ming Zeng, Ye Yang, PhD, Maurizio Zangari, MD, Hongwei Xu, MD, MS, Fenghuang Zhan, MD, PhD

Blood (2011) 118 (21): 2914.

https://doi.org/10.1182/blood.V118.21.2914.2914

Published: 2011

Journal Articles

MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells

Yanyan Gu, MD, PhD, Jonathan L. Kaufman, MD, Lawrence H. Boise, PhD, Sagar Lonial, MD

Blood (2011) 118 (21): 1870.

https://doi.org/10.1182/blood.V118.21.1870.1870

Published: 2011

NARROW

Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation (ASCT) for High-Risk Hematological Malignancies — CPIT-001 Trial

Predicting Treatment Response and Survival of Multiple Myeloma with the Xbp-1 Co-Expression Gene Module

Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins

MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia

Adaptation of Marrow Osteoblast Morphology Mediated By a Hematopoietic-Derived Endosteal Cell Is Critical for Donor HSC Engraftment after BMT

Serum High Expression of Micorna-214 Is a Novel Predictor for Myeloma Bone Disease and Poor Prognosis

Drug Resistant Myeloma Cells Cause More Severe Bone Destruction in Myeloma

Deletion of Sbds from Hematopoietic Progenitors Causes Neutropenia in a Mouse Model of Shwachman-Diamond Syndrome By Specifically Blocking Myeloid Lineage Progression at Late Differentiation Stages

Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma

Sphingolipids As a Novel Target For The Treatment Of Multiple Myeloma

High Trip13 and Low P31 Comet Cause Drug Resistance and Poor Prognosis In Multiple Myeloma

RSK2 Ser227 Is a Therapeutic Target of Myeloma Cells Regardless of Upstream Signalings.

Identification of the Novel Chimeric Gene, PVT1-WWOX , in Multiple Myeloma with 8q24 Abnormality

T-Cell Profiling Shows Marked Differences in Gene Expression Between Tumour Infiltrating (TIL) and Peripheral Blood (PB) Antibody-Bead Selected T-Cells From Fresh Lymph Node and PB Samples in Follicular Non-Hodgkin's Lymphoma (FL): Possible implications for Immunomodulatory Therapy

Anti-Inflammatory, Immuno-Modulatory and Angiostatic Treatment As Third-Line Therapy for Multiple Myeloma (MM) – a Combined Treatment Setting of Lenalidomide with Pioglitazone, Dexamethasone and Low-Dose Treosulfan (phase I/II)

The Expression Pattern of Small Nucleolar and Small Cajal Body-Specific RNAs Characterizes Distinct Molecular Subtypes of Multiple Myeloma

Alterations in the Circulating Nitrite Levels and Expression of NOS Isoforms in the Neutrophils of AML Patients

The Effect of ICAM-1 Antibody Therapy in the SCID-Hu Mouse Model Using Primary Myeloma Cells

MLN4924, An Investigational NAE Inhibitor, Suppresses AKT and mTOR Signaling Pathway Through up Regulating REDD1 in Human Myeloma Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only